相关临床试验
2
0 进行中
药物批准
10
批准总数
监管机构
3
监管机构数
成立时间
1984
已完成
2
100.0%
- LTS Lohmann Therapie-Systeme AG announced expansion of its CDMO portfolio to include ophthalmic drug delivery solutions, leveraging manufacturing capabilities at its Lakewood, New Jersey facility. - The company will initially focus on product development through clinical manufacturing of sterile ophthalmic products in preservative-free multidose devices for chronic and acute eye conditions. - LTS plans to offer comprehensive end-to-end CDMO services for ophthalmic drug products, from formulation development through commercial manufacturing, supporting both U.S. and international regulatory requirements. - The expansion builds on the company's existing aseptic manufacturing expertise in nasal sprays and vials, addressing growing demand for specialized drug delivery solutions in sensitive therapeutic areas.
- LTS LOHMANN Therapie-Systeme AG announced the acquisition of Renaissance Lakewood, a US-based CDMO specializing in nasal sprays and sterile dosage forms. - The acquisition adds approximately 500 employees and state-of-the-art manufacturing infrastructure for unit-dose, bi-dose, and multi-dose nasal sprays to LTS's global network. - Renaissance brings over 20 years of experience in nasal drug delivery and operates comprehensive R&D laboratories supporting formulation development and spray characterization. - The transaction is expected to close before the end of November 2025, subject to regulatory approvals.
- LTS LOHMANN Therapie-Systeme AG and Nualtis announced a strategic collaboration to provide robust, high-quality large-scale manufacturing capabilities for oral thin film drug delivery technologies. - The partnership leverages LTS's global manufacturing expertise to help Nualtis scale their innovative OTF products and deliver them to patients worldwide. - The collaboration combines Nualtis' formulation platform with LTS's manufacturing capabilities to accelerate patient-centric therapeutic solutions across multiple disease indications. - Together, the companies will support pharmaceutical partners through every phase of drug development and commercialization with scalable OTF solutions.
